A method for constructing HPLC-DAD fingerprint of a traditional Chinese medicine compound containing epimedium and its application

By constructing the HPLC-DAD fingerprint map of the Chinese medicine compound, the problem of lack of quality detection and control of the Epimedium Chinese medicine compound in the existing technology is solved, and the efficient quality detection and control of the Chinese medicine compound is achieved, with excellent sensitivity and stability.

CN118376711BActive Publication Date: 2024-11-15GUIZHOU FUHUA PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410497446.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-19
Publication Date
2024-11-15
Estimated Expiration
2044-04-19

AI Technical Summary

Technical Problem

There are no relevant reports on the construction method of the HPLC-DAD fingerprint map containing epimedium in the prior art, and there is a lack of effective quality detection and control methods.

Method used

A method for constructing a Chinese medicine compound HPLC-DAD fingerprint map containing epimedium is provided. By preparing the test sample solution and the reference sample solution, the octadecyl bonded silica gel chromatography column, acetonitrile, methanol and acid water flows. Phase, gradient elution program, detection wavelengths of 200-260 nm, construct the HPLC-DAD fingerprint map of the Chinese medicine compound prescription, and use it for quality control.

Benefits of technology

It has realized the quality testing, quality evaluation and quality control of Chinese medicine compound prescriptions, with excellent sensitivity, stability and repeatability, and can accurately identify and compare the characteristic peaks of Chinese medicine compound prescriptions to ensure product qualification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118376711B_ABST
    Figure CN118376711B_ABST
Patent Text Reader

Abstract

The invention discloses a method for constructing a HPLC-DAD fingerprint spectrum of a Chinese medicine compound containing Epimedium, and the construction method comprises the following steps: according to the result of high-performance liquid phase detection of the test solution and the reference solution, a Chinese medicine compound HPLC-DAD fingerprint spectrum is obtained; the chromatographic conditions of high-performance liquid phase detection are: a chromatographic column with a filler of octadecyl bonded silica gel, a mobile phase A selected from one or more of acetonitrile, methanol and tetrahydrofuran, a mobile phase B being acid water, an alkaline aqueous solution and / or a buffered saline solution, and a gradient elution program of: 0-15min, 15%→25%A; 15-60min, 25%→60%A; a flow rate of 0.5-1.5mL / min, a column temperature of 15-40°C, a detection wavelength of 200-260nm, and a sample volume of 5-15μl. The method has excellent sensitivity, stability, repeatability and accuracy, and can be used for quality detection, quality evaluation or quality control of a Chinese medicine compound containing Epimedium.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a method for constructing an HPLC-DAD fingerprint spectrum of a traditional Chinese medicine compound containing epimedium and an application thereof. Background Art

[0002] There is no report on the method for constructing the HPLC-DAD fingerprint of a traditional Chinese medicine compound containing Epimedium in the prior art. Summary of the invention

[0003] Based on this, the present invention provides a method for constructing an HPLC-DAD fingerprint spectrum of a traditional Chinese medicine compound containing Epimedium, and the construction method comprises the following steps:

[0004] Preparation of the test solution: weigh an appropriate amount of a Chinese herbal compound preparation, grind it into powder, place it in a container of appropriate volume, add a solvent and then perform ultrasonic extraction, let it stand, cool it, add a solvent to make up the weight, shake it well, filter it, and take the filtrate to obtain the test solution; wherein the Chinese herbal compound comprises epimedium, radix dipsaci, rhizoma anemarrhenae, rhizoma rehmanniae, rhizoma sparganii, rhizoma curcumae, rhizoma ligustici, rhizoma rubrae and concha oyster;

[0005] Preparation of reference solution: weigh appropriate amounts of magnolamine, mangiferin, peonidin, paeoniflorin, epimedin A, epimedin B, epimedin C and icariin reference substances, add methanol solution to prepare the reference solution with the concentration of magnolamine, paeoniflorin, paeoniflorin, epimedin A, epimedin B, epimedin C and icariin being 400-600 μg / ml respectively;

[0006] According to the results of high performance liquid chromatography detection of the test solution and the reference solution, a HPLC-DAD fingerprint of the Chinese medicine compound is obtained;

[0007] The chromatographic conditions for high performance liquid phase detection are as follows: a chromatographic column with octadecyl bonded silica gel as filler is used, mobile phase A is selected from one or more of acetonitrile, methanol and tetrahydrofuran, mobile phase B is acid water, alkaline aqueous solution and / or buffered saline solution, and the gradient elution program is: 0-15min, 15%→25%A; 15-60min, 25%→60%A; the flow rate is 0.5-1.5mL / min, the column temperature is 15-40°C, the detection wavelength is 200-260nm, and the injection volume is 5-15μl.

[0008] Furthermore, in the preparation of the test solution, the solvent is water, such as purified water or distilled water.

[0009] Furthermore, the container is a conical flask.

[0010] Furthermore, the mass / volume (g / ml) ratio between the Chinese medicine compound preparation and the first solvent is 0.01-0.5, such as about 0.08 or about 0.02.

[0011] Furthermore, the ultrasonic treatment time is 10 to 60 minutes, for example, about 30 minutes.

[0012] Furthermore, the filtration is microporous membrane filtration.

[0013] Furthermore, the pore size of the microporous filter membrane is 0.45 μm.

[0014] Furthermore, the concentration of magnolamine in the reference solution is 450-550 μg / ml.

[0015] Furthermore, the concentration of mangiferin in the reference solution is 450-550 μg / ml.

[0016] Furthermore, the concentration of albiflorin in the reference solution is 450-550 μg / ml.

[0017] Furthermore, the concentration of paeoniflorin in the reference solution is 450-550 μg / ml.

[0018] Furthermore, the concentration of epimedin A in the reference solution is 450-550 μg / ml.

[0019] Furthermore, the concentration of epimedin B in the reference solution is 450-550 μg / ml.

[0020] Furthermore, the concentration of epimedin C in the reference solution is 450-550 μg / ml.

[0021] Furthermore, the concentration of icariin in the reference solution is 450-550 μg / ml.

[0022] Furthermore, the reference solution is a mixed solution of about 500 μg / ml of magnolidine, about 500 μg / ml of mangiferin, about 500 μg / ml of paeoniflorin, about 500 μg / ml of paeoniflorin, about 500 μg / ml of epimedin A, about 500 μg / ml of epimedin B, about 500 μg / ml of epimedin C and about 500 μg / ml of icariin.

[0023] Furthermore, the flow rate is 0.8-1.2 ml / min, for example, about 1.0 ml / min.

[0024] Furthermore, the column temperature is 20-30°C, for example, about 25°C.

[0025] Furthermore, the detection wavelength is 210-250 nm, for example, 230 nm.

[0026] Furthermore, the injection volume is 8-12 μl, for example, about 10 μl.

[0027] Furthermore, the theoretical plate number of the chromatographic peak corresponding to the reference substance is 5000.

[0028] Furthermore, the separation degree of the chromatographic peak corresponding to the reference substance is equal to 1.5.

[0029] Furthermore, the chromatographic column is a Kromasil 100-5-C18 chromatographic column, a Welch Ultimate XB-C18 chromatographic column or a Diamonsil C18 chromatographic column.

[0030] Furthermore, the chromatographic column is a Kromasil 100-5-C18 chromatographic column.

[0031] Furthermore, the specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.

[0032] Furthermore, the mobile phase A is methanol:acetonitrile=(1:1).

[0033] Furthermore, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution is selected from one or more of weak acids and their salts, weak bases and their salts of different concentrations.

[0034] Further, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution is selected from formic acid, glacial acetic acid, phosphoric acid, trifluoroacetic acid, formic acid and ammonium formate, acetic acid and sodium acetate, acetic acid and ammonium acetate, disodium hydrogen phosphate and sodium dihydrogen phosphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, disodium hydrogen phosphate and citric acid, citric acid and sodium citrate, glycine and hydrochloric acid, or phthalic acid and hydrochloric acid in different concentrations.

[0035] Furthermore, the acid aqueous solution is a 0.08% to 0.12% acid aqueous solution.

[0036] Furthermore, the acid aqueous solution is a 0.08% to 0.12% acetic acid aqueous solution.

[0037] Furthermore, the acid aqueous solution is about 0.1% acetic acid aqueous solution.

[0038] Furthermore, the buffered saline solution is a phosphate aqueous solution and / or an acetate aqueous solution.

[0039] Furthermore, the pH value of the buffered saline solution is not greater than 7.0.

[0040] Furthermore, the preparation method of the Chinese medicine compound preparation comprises: (1) weighing an appropriate amount of oysters and crushing them into oyster fine powder; and (2) weighing an appropriate amount of epimedium, radix dipsaci, rhizoma anemarrhenae, rhizoma rehmanniae, rhizoma sparganii, rhizoma curcumae, rhizoma ligustici and rhizoma peonyii, decocting them with water, filtering, concentrating the filtrate into a clear paste, adding the oyster fine powder, mixing, drying, crushing into fine powder, preparing the preparation, and drying.

[0041] Furthermore, in step (2), appropriate amounts of starch and sucrose are added simultaneously with the oyster powder.

[0042] Furthermore, the mass ratio between the epimedium, the dipsoma, the rhizoma anemarrhenae, the rehmannia root, the trifoliate green, the zedoaria, the rhizome of ligusticum, the rhizome of chuanxiong, the red peony root and the oyster is (500-1000):(20-100):(20-100):(20-100):(20-100):(20-100):(20-100):(20-100):(5-20).

[0043] Further, the mass ratio of the epimedium, the Dipsacus asper, the Anemarrhena asphodeloides, the Rehmannia glutinosa, the Trillium, the Curcuma zedoaria, the Ligusticum chuanxiong, the Paeonia lactiflora and the Oyster is about 650: about 50: about 50: about 40: about 50: about 50: about 50: about 50: about 50: about 10.

[0044] Furthermore, the oyster is a calcined oyster.

[0045] Furthermore, the decocting is performed 1 to 5 times, for example 3 times.

[0046] Furthermore, the decocting time is 0.5 to 3 hours, for example 1 to 2 hours.

[0047] Furthermore, the relative density of the clear paste at 50° C. is 1.2 to 1.40, for example, about 1.35.

[0048] Furthermore, the dosage form of the Chinese medicine compound preparation is granules or capsules.

[0049] Furthermore, the particles are sugar-containing particles or sugar-free particles.

[0050] Furthermore, when the detection wavelength is 230 nm, the fingerprint spectrum includes peaks 1-13, among which peak 2 is magnolamine, peak 3 is mangiferin, peak 4 is paeoniflorin, peak 5 is paeoniflorin, peak 8 is epimedin A, peak 9 is epimedin B, peak 10 is epimedin C, and peak 11 is icariin.

[0051] Furthermore, when the detection wavelength is 230nm, the fingerprint spectrum includes peaks 1-13, among which peak 1 belongs to the medicinal flavor of Dipsacus asper; peaks 3 and 7 belong to the medicinal flavor of Anemarrhena asphodeloides; peaks 2, 8, 9, 10, 11, 12 and 13 belong to the medicinal flavor of Epimedium; peaks 4 and 5 belong to the medicinal flavor of Paeonia lactiflora.

[0052] Further, when the detection wavelength is 230nm, the retention times of peaks 1-13 are 7.906±10%, 10.154±10%, 14.359±10%, 15.240±10%, 18.112±10%, 28.712±10%, 33.823±10%, 44.317±10%, 45.017±10%, 46.294±10%, 46.921±10%, 56.007±10% and 66.515±10%, respectively.

[0053] Further, when the detection wavelength is 230nm, the peak areas of peaks 1-13 are 326893±10%, 3847512±10%, 297337±10%, 1334176±10%, 1598972±10%, 1226905±10%, 1099858±10%, 300925±10%, 366698±10%, 3332369±10%, 1954843±10%, 471566±10% and 600721±10%, respectively.

[0054] Furthermore, at the detection wavelength of 230 nm, the fingerprint spectrum includes 13 characteristic peaks, with the chromatographic peak No. 5, paeoniflorin, as the reference peak, and the relative retention times of the other 21 characteristic peaks are 0.433±10% for chromatographic peak No. 1, 0.568±10% for chromatographic peak No. 2, 0.792±10% for chromatographic peak No. 3, 0.840±10% for chromatographic peak No. 4, 1.548±10% for chromatographic peak No. 6, 1.877±10% for chromatographic peak No. 7, 2.453±10% for chromatographic peak No. 8, 2.498±10% for chromatographic peak No. 9, 2.561±10% for chromatographic peak No. 10, 2.598±10% for chromatographic peak No. 11, 3.110±10% for chromatographic peak No. 12 and 3.699±10% for chromatographic peak No. 13.

[0055] According to another aspect of the present invention, a quality control method for a Chinese medicinal compound containing Epimedium is provided, the quality control method comprising the following steps:

[0056] (1) Establishing a standard HPLC-DAD fingerprint of a Chinese medicine compound reference sample according to the above-mentioned HPLC-DAD fingerprint construction method;

[0057] (2) taking a solution of a Chinese medicine compound test sample and testing it according to the chromatographic conditions in the above-mentioned HPLC-DAD fingerprint construction method to obtain an HPLC-DAD fingerprint of the Chinese medicine compound test sample; and

[0058] (3) Compare the HPLC-DAD fingerprint of the Chinese medicine compound sample obtained in step (2) with the HPLC-DAD fingerprint of the Chinese medicine compound reference sample obtained in step (1). If the fingerprint meets the requirements, it is a qualified product; if the fingerprint does not meet the requirements, it is an unqualified product.

[0059] Furthermore, the compliance requirement includes one or more of the following:

[0060] (1) When the detection wavelength is 230 nm, the HPLC-DAD fingerprint spectrum of the Chinese medicine compound sample to be tested exhibits 13 characteristic chromatographic peaks, and the retention time of each characteristic chromatographic peak is within ±10% of the retention time value of the corresponding reference chromatographic peak in the standard HPLC-DAD fingerprint spectrum of the Chinese medicine compound reference sample;

[0061] (2) When the detection wavelength is 230 nm, with the paeoniflorin peak as the S peak, the relative retention time of each characteristic chromatographic peak in the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested and the S peak is within ±10% of the relative retention time value of each characteristic chromatographic peak in the standard HPLC-DAD fingerprint of the Chinese medicine compound reference sample; and

[0062] (3) According to the Chinese medicine chromatographic HPLC-DAD fingerprint similarity evaluation system, the similarity between the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested and the standard HPLC-DAD fingerprint of the Chinese medicine compound reference sample shall be calculated, and the similarity shall not be less than 0.90.

[0063] According to another aspect of the present invention, there is provided a use of the above construction method or the above quality control method in quality detection, quality evaluation or quality control of a traditional Chinese medicine compound containing Epimedium.

[0064] Beneficial effects of the present invention:

[0065] The method of the invention has excellent sensitivity, stability, repeatability and accuracy, and can be used for quality detection, quality evaluation or quality control of a traditional Chinese medicine compound containing epimedium. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without exceeding the scope of protection required by the present invention.

[0067] Figure 1 The following is a schematic diagram of the results of the investigation of different extraction solvents, where A is 70% methanol extraction, B is pure water extraction, and C is 80% methanol extraction.

[0068] Figure 2 This is a statistical chart of the number of chromatographic peaks of different extraction solvents of Chinese herbal compound granules containing Epimedium.

[0069] Figure 3 The following is a schematic diagram of the investigation results of different treatment methods. A is water extraction without extraction, B is water extraction with n-butanol solution extraction, and C is water extraction followed by ammonia washing.

[0070] Figure 4 This is a statistical chart of the number of chromatographic peaks of different processing methods of Chinese herbal compound granules containing Epimedium.

[0071] Figure 5 The figure is a schematic diagram of the investigation results of different mobile phases. Among them, A is methanol-acetonitrile-water as the mobile phase, and B is acetonitrile-water as the mobile phase.

[0072] Figure 6 This is a schematic diagram of the investigation results of gradient elution condition 1, where A is 230 nm and B is 260 nm.

[0073] Figure 7 This is a schematic diagram of the investigation results of gradient elution condition 2, where A is 230 nm and B is 260 nm.

[0074] Figure 8 The figure is a schematic diagram of the investigation results of gradient elution condition 3, wherein A is 230 nm and B is 260 nm.

[0075] Fig. 9 The figure is a schematic diagram of the investigation results of gradient elution condition 4. A is 230 nm (particles), B is 260 nm (particles), C is 230 nm (capsules), and D is 260 nm (capsules).

[0076] Fig.10 The following is a schematic diagram of the results of the investigation of different chromatographic columns. A is a Kromasil 100-5-C18 chromatographic column, B is a Welch Ultimate XB-C18 chromatographic column, and C is a Diamonsil C18 chromatographic column.

[0077] Fig.11 The HPLC characteristic spectra of 30 batches of Chinese herbal compound test sample solutions containing epimedium, wherein A is the HPLC characteristic spectra of 10 batches of sugar-free Chinese herbal compound granules containing epimedium, B is the HPLC characteristic spectra of 10 batches of sugar-containing Chinese herbal compound granules containing epimedium, and C is the HPLC characteristic spectra of 10 batches of Chinese herbal compound capsules containing epimedium.

[0078] Fig.12 The characteristic spectrum of the Chinese herbal compound reference extract containing Epimedium, wherein A is the chromatogram of the mixed reference substance and B is the chromatogram of the sample.

[0079] Fig.13 Schematic diagram of the chromatographic peak attribution results. Among them, A is the attribution of the characteristic peak of the traditional Chinese medicine compound containing epimedium to the components of Anemarrhena asphodeloides and Dipsacus asper, B is the attribution of the characteristic peak of the traditional Chinese medicine compound containing epimedium to the components of Epimedium, C is the attribution of the components of Paeonia lactiflora in the characteristic peak of the traditional Chinese medicine compound containing epimedium, D is the attribution of the components of Trillium and Rehmanniae in the characteristic peak of the traditional Chinese medicine compound containing epimedium, and E is the attribution of the components of Chuanxiong and Curcuma in the characteristic peak of the traditional Chinese medicine compound containing epimedium. DETAILED DESCRIPTION

[0080] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.

[0081] Unless otherwise indicated, all technical and scientific terms and abbreviations used herein have the meanings commonly understood by those of ordinary skill in the field of the invention or the field in which the terms are used. Although any methods, conditions, substances or materials similar to or equivalent to those disclosed herein may be used in the practice of the present invention, preferred methods, conditions, substances or materials are described herein.

[0082] The present invention is intended to encompass all alternatives, variations and equivalents that may be included in the present invention as defined by the claims. Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein that can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described.

[0083] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0084] In the present invention, the term "comprising" is synonymous with "including". As used herein, the terms "comprising", "including", "having", "containing" or any other variation thereof are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus comprising the listed elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.

[0085] As described in the background technology section, there is no report on the construction method of HPLC-DAD fingerprint spectrum of a traditional Chinese medicine compound containing epimedium in the prior art. In order to solve the above problem, the present invention provides a method for constructing HPLC-DAD fingerprint spectrum of a traditional Chinese medicine compound containing epimedium, and the construction method comprises the following steps:

[0086] Preparation of the test solution: weigh an appropriate amount of a Chinese herbal compound preparation, grind it into powder, place it in a container of appropriate volume, add a solvent and then perform ultrasonic extraction, let it stand, cool it, add a solvent to make up the weight, shake it well, filter it, and take the filtrate to obtain the test solution; wherein the Chinese herbal compound comprises epimedium, radix dipsaci, rhizoma anemarrhenae, rhizoma rehmanniae, rhizoma sparganii, rhizoma curcumae, rhizoma ligustici, rhizoma rubrae and concha oyster;

[0087] Preparation of reference solution: weigh appropriate amounts of magnolamine, mangiferin, peonidin, paeoniflorin, epimedin A, epimedin B, epimedin C and icariin reference substances, add methanol solution to prepare the reference solution with the concentration of magnolamine, paeoniflorin, paeoniflorin, epimedin A, epimedin B, epimedin C and icariin being 400-600 μg / ml respectively;

[0088] According to the results of high performance liquid chromatography detection of the test solution and the reference solution, a HPLC-DAD fingerprint of the Chinese medicine compound is obtained;

[0089] The chromatographic conditions for high performance liquid phase detection are as follows: a chromatographic column with octadecyl bonded silica gel as filler is used, mobile phase A is selected from one or more of acetonitrile, methanol and tetrahydrofuran, mobile phase B is acid water, alkaline aqueous solution and / or buffered saline solution, and the gradient elution program is: 0-15min, 15%→25%A; 15-60min, 25%→60%A; the flow rate is 0.5-1.5mL / min, the column temperature is 15-40°C, the detection wavelength is 200-260nm, and the injection volume is 5-15μl.

[0090] In the present invention, when concentration, flow rate, column temperature, injection volume, temperature, ratio, time, volume, number of times, or other values ​​or parameters are expressed as ranges, preferred ranges, or a series of upper preferred values ​​and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when the range "15-40" is disclosed, the described range should be interpreted as including the range "15-40", "15-35", "15-30", "15-25", "15-20", "20-40", "20-35", "20-30", "20-25", "25-40", "25-35", "25-30", "30-40", "30-35", "35-40", etc. When a numerical range is described herein, unless otherwise stated, the range is intended to include its end values ​​and all integers and fractions within the range.

[0091] In a preferred embodiment, in the preparation of the test solution, the solvent is water, such as purified water or distilled water.

[0092] In a preferred embodiment, the container is a conical flask.

[0093] In a preferred embodiment, the mass / volume (g / ml) ratio between the Chinese medicine compound preparation and the first solvent is 0.01-0.5, such as about 0.08 or about 0.02.

[0094] In the present invention, "about" refers to a value within the range of ±5% of a specific value. For example, "about 0.08" includes ±5% of 0.08, or from 0.076 to 0.084; "about 0.02" includes ±5% of 0.02, or from 0.019 to 0.021.

[0095] In a preferred embodiment, the ultrasonic treatment time is 10 to 60 minutes, such as about 30 minutes.

[0096] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 30" includes ±5% of 30, or from 28.5 to 31.5.

[0097] In a preferred embodiment, the filtration is microporous membrane filtration.

[0098] In a preferred embodiment, the pore size of the microporous filter membrane is 0.45 μm.

[0099] In a preferred embodiment, the concentration of magnolidine in the reference solution is 450-550 μg / ml.

[0100] In a preferred embodiment, the concentration of mangiferin in the reference solution is 450-550 μg / ml.

[0101] In a preferred embodiment, the concentration of albiflorin in the reference solution is 450-550 μg / ml.

[0102] In a preferred embodiment, the concentration of paeoniflorin in the reference solution is 450-550 μg / ml.

[0103] In a preferred embodiment, the concentration of epimedin A in the reference solution is 450-550 μg / ml.

[0104] In a preferred embodiment, the concentration of epimedin B in the reference solution is 450-550 μg / ml.

[0105] In a preferred embodiment, the concentration of epimedin C in the reference solution is 450-550 μg / ml.

[0106] In a preferred embodiment, the concentration of icariin in the reference solution is 450-550 μg / ml.

[0107] In a preferred embodiment, the reference substance solution is a mixed solution of about 500 μg / ml of magnolidine, about 500 μg / ml of mangiferin, about 500 μg / ml of paeoniflorin, about 500 μg / ml of paeoniflorin, about 500 μg / ml of epimedin A, about 500 μg / ml of epimedin B, about 500 μg / ml of epimedin C and about 500 μg / ml of icariin.

[0108] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 500" includes ±5% of 500, or from 475 to 525.

[0109] In a preferred embodiment, the flow rate is 0.8-1.2 ml / min, such as about 1.0 ml / min.

[0110] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 1.0" includes ±5% of 1.0, or from 0.95 to 1.05.

[0111] In a preferred embodiment, the column temperature is 20-30°C, such as about 25°C.

[0112] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 25" includes ±5% of 25, or from 23.75 to 26.25.

[0113] In a preferred embodiment, the detection wavelength is 210-250 nm, for example, 230 nm.

[0114] In a preferred embodiment, the injection volume is 8-12 μl, such as about 10 μl.

[0115] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 10" includes ±5% of 10, or from 9.5 to 10.5.

[0116] In a preferred embodiment, the theoretical plate number of the chromatographic peak corresponding to the reference substance is 5000.

[0117] In a preferred embodiment, the separation degree of the chromatographic peak corresponding to the reference substance is equal to 1.5.

[0118] In a preferred embodiment, the chromatographic column is a Kromasil 100-5-C18 chromatographic column, a Welch Ultimate XB-C18 chromatographic column or a Diamonsil C18 chromatographic column.

[0119] In a preferred embodiment, the chromatographic column is a Kromasil 100-5-C18 chromatographic column.

[0120] In a preferred embodiment, the specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.

[0121] In a preferred embodiment, the mobile phase A is methanol:acetonitrile=(1:1).

[0122] In a preferred embodiment, the acid aqueous solution, base aqueous solution and / or buffered saline solution is selected from one or more of weak acids and their salts, weak bases and their salts of different concentrations.

[0123] In a preferred embodiment, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution is selected from formic acid, glacial acetic acid, phosphoric acid, trifluoroacetic acid, formic acid and ammonium formate, acetic acid and sodium acetate, acetic acid and ammonium acetate, disodium hydrogen phosphate and sodium dihydrogen phosphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, disodium hydrogen phosphate and citric acid, citric acid and sodium citrate, glycine and hydrochloric acid, or phthalic acid and hydrochloric acid in different concentrations.

[0124] In a preferred embodiment, the acid aqueous solution is a 0.08% to 0.12% acid aqueous solution.

[0125] In a preferred embodiment, the acid aqueous solution is a 0.08% to 0.12% acetic acid aqueous solution.

[0126] In a preferred embodiment, the aqueous acid solution is about 0.1% acetic acid in water.

[0127] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 0.1%" includes ±5% of 0.1%, or from 0.095% to 0.105%.

[0128] In a preferred embodiment, the buffered saline solution is a phosphate aqueous solution and / or an acetate aqueous solution.

[0129] In a preferred embodiment, the pH value of the buffered saline solution is not greater than 7.0.

[0130] In a preferred embodiment, the preparation method of the Chinese medicine compound preparation comprises: (1) weighing an appropriate amount of oysters and crushing them into oyster fine powder; and (2) weighing an appropriate amount of epimedium, Dipsacus asper, Anemarrhena asphodeloides, Rehmannia root, Trillium, Curcuma zedoaria, Ligusticum chuanxiong and Paeonia lactiflora, decocting with water, filtering, concentrating the filtrate into a clear paste, adding the oyster fine powder, mixing, drying, crushing into fine powder, making a preparation, and drying.

[0131] In a preferred embodiment, in step (2), appropriate amounts of starch and sucrose are added simultaneously with the addition of the oyster powder.

[0132] In a preferred embodiment, the mass ratio of the epimedium, the dipsacus, the rhizoma anemarrhenae, the rehmannia root, the trifoliate green, the zedoaria, the rhizome of ligusticum, the rhizome of chuanxiong, the red peony root and the oyster is (500-1000):(20-100):(20-100):(20-100):(20-100):(20-100):(20-100):(20-100):(5-20).

[0133] In a preferred embodiment, the mass ratio of the Epimedium, the Dipsacus asper, the Anemarrhena asphodeloides, the Rehmannia glutinosa, the Trillium, the Curcuma, the Ligusticum chuanxiong, the Red Peony Root and the Oyster is about 650: about 50: about 50: about 40: about 50: about 50: about 50: about 50: about 50: about 10.

[0134] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 650" includes ±5% of 650, or from 617.5 to 682.5; "about 50" includes ±5% of 50, or from 47.5 to 52.5; "about 40" includes ±5% of 40, or from 38 to 42; "about 10" includes ±5% of 10, or from 9.5 to 10.5.

[0135] In a preferred embodiment, the oyster is calcined oyster.

[0136] In a preferred embodiment, the decocting is performed 1 to 5 times, for example 3 times.

[0137] In a preferred embodiment, the decocting time is 0.5 to 3 hours, such as 1 to 2 hours.

[0138] In a preferred embodiment, the relative density of the clear paste at 50° C. is 1.2-1.40, for example, about 1.35.

[0139] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 1.35" includes ±5% of 1.35, or from 1.2825 to 1.4175.

[0140] In a preferred embodiment, the dosage form of the Chinese medicine compound preparation is granules or capsules.

[0141] In a preferred embodiment, the particles are sugar-containing particles or sugar-free particles.

[0142] In a preferred embodiment, the particles are Gusongbao particles.

[0143] In a preferred embodiment, when the detection wavelength is 230 nm, the fingerprint spectrum includes peaks 1-13, wherein peak 2 is magnolidine, peak 3 is mangiferin, peak 4 is paeoniflorin, peak 5 is paeoniflorin, peak 8 is epimedin A, peak 9 is epimedin B, peak 10 is epimedin C, and peak 11 is icariin.

[0144] In a preferred embodiment, when the detection wavelength is 230nm, the fingerprint spectrum includes peaks 1-13, wherein peak 1 belongs to the medicinal flavor of Dipsacus asper; peaks 3 and 7 belong to the medicinal flavor of Anemarrhena asphodeloides; peaks 2, 8, 9, 10, 11, 12, and 13 belong to the medicinal flavor of Epimedium; and peaks 4 and 5 belong to the medicinal flavor of Paeonia lactiflora.

[0145] In a preferred embodiment, when the detection wavelength is 230 nm, the retention times of peaks 1-13 are 7.906±10%, 10.154±10%, 14.359±10%, 15.240±10%, 18.112±10%, 28.712±10%, 33.823±10%, 44.317±10%, 45.017±10%, 46.294±10%, 46.921±10%, 56.007±10% and 66.515±10%, respectively.

[0146] In a preferred embodiment, when the detection wavelength is 230 nm, the peak areas of peaks 1-13 are 326893±10%, 3847512±10%, 297337±10%, 1334176±10%, 1598972±10%, 1226905±10%, 1099858±10%, 300925±10%, 366698±10%, 3332369±10%, 1954843±10%, 471566±10% and 600721±10%, respectively.

[0147] In a preferred embodiment, when the detection wavelength is 230nm, the fingerprint spectrum includes 13 characteristic peaks, with the chromatographic peak of paeoniflorin No. 5 as the reference peak, and the relative retention times of the other 21 characteristic peaks are 0.433±10% for chromatographic peak No. 1, 0.568±10% for chromatographic peak No. 2, 0.792±10% for chromatographic peak No. 3, 0.840±10% for chromatographic peak No. 4, 1.548±10% for chromatographic peak No. 6, 1.877±10% for chromatographic peak No. 7, 2.453±10% for chromatographic peak No. 8, 2.498±10% for chromatographic peak No. 9, 2.561±10% for chromatographic peak No. 10, 2.598±10% for chromatographic peak No. 11, 3.110±10% for chromatographic peak No. 12 and 3.699±10% for chromatographic peak No. 13.

[0148] According to another aspect of the present invention, a quality control method for a Chinese medicinal compound containing Epimedium is provided, the quality control method comprising the following steps:

[0149] (1) Establishing a standard HPLC-DAD fingerprint of a Chinese medicine compound reference sample according to the above-mentioned HPLC-DAD fingerprint construction method;

[0150] (2) taking a solution of a Chinese medicine compound test sample and testing it according to the chromatographic conditions in the above-mentioned HPLC-DAD fingerprint construction method to obtain an HPLC-DAD fingerprint of the Chinese medicine compound test sample; and

[0151] (3) Compare the HPLC-DAD fingerprint of the Chinese medicine compound sample obtained in step (2) with the HPLC-DAD fingerprint of the Chinese medicine compound reference sample obtained in step (1). If the fingerprint meets the requirements, it is a qualified product; if the fingerprint does not meet the requirements, it is an unqualified product.

[0152] In a preferred embodiment, the compliance requirements include one or more of the following:

[0153] (1) When the detection wavelength is 230 nm, the HPLC-DAD fingerprint spectrum of the Chinese medicine compound sample to be tested exhibits 13 characteristic chromatographic peaks, and the retention time of each characteristic chromatographic peak is within ±10% of the retention time value of the corresponding reference chromatographic peak in the standard HPLC-DAD fingerprint spectrum of the Chinese medicine compound reference sample;

[0154] (2) When the detection wavelength is 230 nm, with the paeoniflorin peak as the S peak, the relative retention time of each characteristic chromatographic peak in the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested and the S peak is within ±10% of the relative retention time value of each characteristic chromatographic peak in the standard HPLC-DAD fingerprint of the Chinese medicine compound reference sample; and

[0155] (3) According to the Chinese medicine chromatographic HPLC-DAD fingerprint similarity evaluation system, the similarity between the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested and the standard HPLC-DAD fingerprint of the Chinese medicine compound reference sample shall be calculated, and the similarity shall not be less than 0.90.

[0156] According to another aspect of the present invention, there is provided a use of the above construction method or the above quality control method in quality detection, quality evaluation or quality control of a traditional Chinese medicine compound containing Epimedium.

[0157] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions or conditions recommended by the manufacturer.

[0158] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0159] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in this patent specification can be used in combination with any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.

[0160] Example

[0161] 1. Instruments and reagents

[0162] 1.1 Experimental instruments

[0163] Waters e2695 high performance liquid chromatograph (Waters, USA); XSE 105DU electronic analytical balance (Mettler, Switzerland); KQ-250DB numerically controlled ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.); 3 chromatographic columns of different brands, the specific information of which is shown in Table 1.

[0164] Table 1 Column information

[0165] Serial number Column name Part No. Serial No. 1 Kromasil 100-5-C18 M05CLA25 E403668 5μm, 250mm×4.6mm 2 Welch Ultimate XB-C18 00207-31043 60190601538 5μm, 250mm×4.6mm 3 Diamonsil C18 99603 6010773 5μm, 250mm×4.6mm

[0166] 1.2 Reagents and medicinal materials

[0167] Methanol (Thermo Fisher Scientific China Ltd.), acetonitrile (Thermo Fisher Scientific China Ltd.), purified water (Guangzhou Watsons Food & Beverage Co., Ltd.), acetic acid (Thermo Fisher Scientific China Ltd.), magnolamine (batch number: RFS-M02602101009), mangiferin (batch number: RFS-M01802011021), paeoniflorin (batch number: RFS-S01102204022), epimedin A (batch number: RFS-C01311804027), epimedin B (batch number: RFS-C01211804027), epimedin C (batch number: RFS-C01111803006), icariin (batch number: RFS-Y00411803005), and anemarrhena saponin BⅡ (batch number: RFS-Z00402207029). The above reference substances were purchased from Chengdu Ruifensidedan Biotechnology Co., Ltd., HPLC grade, and the contents were all >98% calculated by HPLC area normalization method. Paeoniflorin (batch number: 110736-201842) was purchased from China Food and Drug Biological Products Control Institute. There are 20 batches of Chinese herbal compound granules containing Epimedium (sugar-free: GSBWT001, GSBWT002, GSBWT003, GSBWT004, GSBWT005, GSBWT006, GSBWT007, GSBWT008, GSBWT009, GSBWT010 sugar-containing: GSBYT001, GSBYT002, GSBYT003, GSBYT004, GSBYT 005, GSBYT006, GSBYT007, GSBYT008, GSBYT009, GSBYT010), and ten batches of Chinese herbal compound capsules containing epimedium (GSBJN001, GSBJN002, GSBJN003, GSBJN004, GSBJN005, GSBJN006, GSBJN007, GSBJN008, GSBJN009, GSBJN010) came from Guizhou Fuhua Pharmaceutical.

[0168] 2. Method optimization

[0169] 2.1. Investigation of different extraction solvents

[0170] Weigh three samples of the same batch of Chinese medicine compound granules containing Epimedium, dissolve them in 25 mL of 70% methanol, pure water, and 80% methanol, extract them by ultrasonic for 30 min, filter them with a 0.45 μm filter membrane, set aside, and inject them for analysis. The chromatograms of different extraction solvents are shown in Figure 2. Figure 1 The statistical results of the number of characteristic peaks obtained by different extraction solvents are shown in Figure 2 shown.

[0171] The comparison results of different extraction solvents show that when pure water is used as the extraction solvent, the number and peak height of the obtained sample chromatographic peaks are higher than those of the samples extracted with 70% methanol and 80% methanol, indicating that the water extraction effect is better than that of 70% methanol and 80% methanol extraction, thus determining that pure water is the best extraction solvent.

[0172] 2.2. Investigation of sample pretreatment methods

[0173] 2.2.1. Water extraction without extraction

[0174] Take about 2 g of the Chinese herbal compound granules containing Epimedium, weigh them accurately, put them in a 50 mL conical flask, add 25 mL of pure water accurately, perform ultrasonic extraction for 30 minutes, take them out, cool them, weigh them again, shake them well, filter them, and you are done.

[0175] 2.2.2 Water extraction and n-butanol solution extraction

[0176] Take about 2g of the Chinese medicine compound granules containing Epimedium, weigh accurately, place in a 50mL conical flask, accurately add 25mL of purified water, ultrasonically extract for 30min, take out, cool, weigh again, shake well, and filter. Take the filtrate and place it in a separatory funnel, extract it three times with n-butanol saturated with water, combine the n-butanol layers, evaporate to dryness, dissolve with methanol and make up to 5mL volumetric flask, shake well, filter with a 0.45μm microporous filter membrane, and take the filtrate to obtain.

[0177] 2.2.3. Water extraction followed by ammonia washing

[0178] Take about 2g of the Chinese medicine compound granules containing Epimedium, weigh accurately, place in a 100mL conical flask, accurately add 25mL of purified water, ultrasonically extract for 30min, take out, cool, weigh again, shake well, and filter. Take the filtrate and place it in a separatory funnel, extract it 3 times with water-saturated n-butanol, combine the n-butanol layers, wash the n-butanol solution three times with an ammonia solution, evaporate the n-butanol solution, dissolve it with methanol and make it up to 5mL volumetric flask, shake well, filter it with a 0.45μm microporous filter membrane, and take the filtrate to obtain.

[0179] The chromatogram information obtained by different processing methods is as follows Figure 3 The statistical results of the number of characteristic peaks obtained by the three processing methods are shown in Figure 4 shown.

[0180] The results of different sample pretreatment methods showed that when water extraction was used without extraction, the number and peak height of the obtained sample chromatographic peaks were higher than those of the other two treatment methods, thus determining that simple water extraction was the best treatment method.

[0181] 2.3. Investigation of different mobile phases

[0182] Weigh two samples of the same batch of traditional Chinese medicine compound granules containing Epimedium, and use methanol-acetonitrile-water and acetonitrile-water as the mobile phase elution system for sample injection analysis. The chromatograms of different mobile phases are shown in Figure 2. Figure 5 shown.

[0183] The above measurement results show that the methanol-acetonitrile-water elution system has more chromatographic peaks, faster peak elution, better peak shape, reasonable overall peak elution time distribution, stable baseline, and better chromatographic peak separation than acetonitrile-water elution. Therefore, it is better to use the methanol-acetonitrile-water elution system as the mobile phase.

[0184] 2.4. Investigation of different gradient elution conditions

[0185] In this experiment, methanol:acetonitrile = 1:1 and 0.1% acetic acid water were used as the mobile phase for separation conditions. The details are shown below.

[0186] Condition 1 A: Methanol: Acetonitrile = 1:1 B: 0.1% acetic acid water

[0187] 0~45min 15%~80% A 85%~20% B

[0188] 45~55min 80%~90% A 20%~10% B

[0189] like Figure 6 As shown, under the above elution condition 1, the obtained chromatographic peaks appeared too early, most of the chromatographic peaks appeared before 30 minutes, the overall chromatographic peak distribution was unreasonable, and the separation was poor;

[0190]

[0191] like Figure 7 As shown, under the above elution condition 2, the obtained chromatographic peaks emerge too late, and most of them emerge after 30 minutes. The overall chromatographic peak distribution is unreasonable, the separation is poor, and the baseline is not flat.

[0192] Condition 3 A: Methanol: Acetonitrile = 1:1 B: 0.1% acetic acid water

[0193] 0~60min 15%~70%A 85%~30%B

[0194] like Figure 8As shown, under the above elution condition 3, the chromatographic peaks obtained have poor separation at retention times of 8-10 minutes, 30 minutes, etc., and have not achieved baseline separation;

[0195] Condition 4 A: Methanol: Acetonitrile = 1:1 B: 0.1% acetic acid water

[0196] 0~15min 15%~25% A 85%~75% B

[0197] 15~60min 25%~60% A 75%~40% B

[0198] like Fig. 9 As shown, under the above elution condition 4, the number of chromatographic peaks obtained is large, the overall layout is reasonable, and the baseline is relatively flat. Compared with the chromatographic condition 3, the separation of the target chromatographic peaks at retention time 8-10 minutes is improved, and the separation of the target chromatographic peaks at 34-36 minutes has reached baseline separation. Under the chromatographic condition 4, the chromatogram of the Chinese herbal compound capsule containing epimedium also has good peaks, reasonable layout, and a flat baseline, so the elution condition 4 is determined to be the optimal elution gradient.

[0199] 2.5. Investigation of different chromatographic columns

[0200] This study compared three different types of C-18 columns. The chromatograms obtained from different columns are shown in Figure 2. Fig.10 As shown in the figure, Kromasil 100-5-C18 obtained 27 chromatographic peaks, Welch Ultimate XB-C18 obtained 22 chromatographic peaks, and Diamonsil C18 obtained 17 chromatographic peaks. By comparing the chromatograms of different columns, it can be seen that the Kromasil 100-5-C18 chromatographic column has the largest number of chromatographic peaks, the largest amount of chromatographic peak information, and the best separation, so the Kromasil100-5-C18 chromatographic column was finally selected.

[0201] 3. Establishment of characteristic fingerprint

[0202] 3.1. Preparation of test solution

[0203] Take an appropriate amount of Chinese herbal compound granules containing epimedium, grind, take about 2 g of powder, accurately weigh, put it in a conical flask, add about 25 mL of pure water, weigh, ultrasonically extract for 30 minutes, let it stand and cool, add pure water to weigh, shake well, filter through a 0.45 μm filter membrane, and take the filtrate to obtain.

[0204] Take an appropriate amount of Chinese herbal compound capsules containing Epimedium, take about 0.5g of powder, accurately weigh, put it in a conical flask, add about 25mL of pure water, weigh, ultrasonically extract for 30min, let it stand and cool, add pure water to make up the weight, shake well, filter through a 0.45μm filter membrane, and take the filtrate to obtain.

[0205] 3.2 Preparation of reference solution

[0206] Accurately weigh appropriate amounts of magnolidine, mangiferin, paeoniflorin, paeoniflorin, epimedin A, epimedin B, epimedin C, icariin, and reference substance, and dissolve them in methanol.

[0207] 3.3 Chromatographic conditions

[0208] Octadecylsilane bonded silica gel was used as the filler; methanol:acetonitrile = 1:1 was used as the mobile phase A, and 0.1% acetic acid solution was used as the mobile phase B; the chromatographic column was Kromasil 100-5-C18 (4.6mm×250mm, 5um); gradient elution (0-15min, 15%-25%A; 15-60min, 25%-60%A); column temperature: 25°C; volume flow rate: 1.0mL / min; injection volume: 10μl.

[0209] 3.4. Feature Spectrum Methodology

[0210] 3.4.1. Investigation of precision

[0211] The same test solution was accurately aspirated and injected 6 times continuously according to the chromatographic conditions in Item 3.3 (2695 HPLC, Kromasil C18 chromatographic column, the same below). The RSD of the retention time of each common peak was <1.69%, and the RSD of the peak area was <2.2%. This shows that the precision of the instrument meets the requirements, as shown in Table 2 and Table 3.

[0212] Table 2 Precision investigation results

[0213]

[0214]

[0215] Table 3 Precision investigation results

[0216]

[0217] 3.4.2. Stability Investigation

[0218] Prepare the test solution according to the method under 3.1, accurately pipette the same test solution, and inject 10 μL each time at 0, 2, 4, 8, 12, and 24 hours, and measure according to the chromatographic conditions of the above method. The RSD of the retention time of each common peak is <1.60%, and the RSD of the peak area is <2.49%. It shows that the test solution has good stability within 24 hours, as shown in Table 4 and Table 5.

[0219] Table 4 Stability test results

[0220]

[0221] Table 5 Stability test results

[0222]

[0223]

[0224] 3.4.3. Repeatability Investigation

[0225] Take the same batch of Chinese medicine compound granules containing epimedium, prepare 6 test solutions according to the method under 3.1, inject 10μL each time, and measure according to the chromatographic conditions of the above method. The RSD of the retention time of each common peak is <1.79%, and the RSD of the peak area is <2.19%. It shows that the repeatability is good, as shown in Table 6 and Table 7.

[0226] Table 6 Repeatability test results

[0227]

[0228] Table 7 Repeatability test results

[0229]

[0230]

[0231] 4. Feature Spectrum Analysis

[0232] 4.1. Feature Spectrum Generation

[0233] Take 30 batches of Chinese medicine compound test solutions containing Epimedium, and measure them according to the conditions under 3.3. Use the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" (2012 Edition) software to analyze the sample characteristic spectrum. Use the characteristic spectrum of sample S1 as the reference spectrum for fingerprint matching (median method, time window 0.1min), and identify 13 characteristic peaks, such as Fig.11 As shown. Based on the relative retention time of each characteristic peak of 10 batches of reference samples, the characteristic spectrum identification standard of the traditional Chinese medicine compound containing Epimedium was determined. Peak 5 was used as the reference peak. The relative retention time of each characteristic peak and the reference peak should have a deviation within ±10% of the specified value. The specified values ​​of the relative retention time of each chromatographic peak are 0.433 (peak 1), 0.568 (peak 2), 0.792 (peak 3), 0.840 (peak 4), 1.000 (peak 5), 1.584 (peak 6), 1.877 (peak 7), 2.453 (peak 8), 2.498 (peak 9), 2.561 (peak 10), 2.598 (peak 11), 3.110 (peak 12), 3.699 (peak 13), as shown in Table 8.

[0234] Table 8 Calculation results of relative retention time of common fingerprint peaks of 10 batches of Chinese herbal compound granules containing Epimedium

[0235]

[0236]

[0237] 4.2 Identification and attribution of chromatographic peaks

[0238] The retention time of each chromatographic peak of the reference mixed solution and the sample chromatogram is compared. Fig.12 As shown, eight characteristic peaks were identified, namely magnolidine (peak 2), mangiferin (peak 3), paeoniflorin (peak 4), paeoniflorin (peak 5), epimedin A (peak 8), epimedin B (peak 9), epimedin C (peak 10), and icariin (peak 11).

[0239] After comparing the retention time and UV absorption characteristics of the corresponding chromatographic peaks in the single herbal medicine, combined with the information of the reference substance, the characteristic peaks are attributed as follows: Peak 1 comes from Dipsacus asper ( Fig.13 A); Peak 3 and Peak 7 are from Anemarrhena asphodeloides ( Fig.13 A); Peak 2, Peak 8, Peak 9, Peak 10, Peak 11, Peak 12, Peak 13 are from Epimedium ( Fig.13 B); Peaks 4 and 5 are from red peony root ( Fig.13 C). Thus, the characteristic spectrum method of the present invention can be used for quality control of four medicinal materials, namely, Epimedium, Dipsacus asper, Anemarrhena asphodeloides, and Paeonia lactiflora in a traditional Chinese medicine compound containing Epimedium.

[0240] The embodiments of the present invention are described in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea. At the same time, changes or deformations made by those skilled in the art based on the ideas of the present invention, the specific implementation methods and application scope of the present invention, all belong to the scope of protection of the present invention. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A method for constructing an HPLC-DAD fingerprint of a Chinese medicinal compound containing Epimedium, characterized in that: The construction method comprises the following steps: Preparation of the test solution: weigh an appropriate amount of a Chinese herbal compound preparation, grind it into powder, place it in a container of appropriate volume, add water and then perform ultrasonic extraction, let it stand, cool it, add a solvent to make up the weight, shake it well, filter it, and take the filtrate to obtain the test solution; wherein the Chinese herbal compound comprises epimedium, radix dipsaci, rhizoma anemarrhenae, rhizoma rehmanniae, rhizoma trillium, rhizoma curcumae, rhizoma ligustici chuanxiong, rhizoma rubrae and concha oyster; Preparation of reference solution: weigh appropriate amounts of magnolamine, mangiferin, peonidin, paeoniflorin, epimedin A, epimedin B, epimedin C and icariin reference substances, add methanol solution to prepare the reference solution with a concentration of magnolamine, paeoniflorin, paeoniflorin, epimedin A, epimedin B, epimedin C and icariin of 400 to 600 μg / ml respectively; According to the results of high performance liquid phase detection of the test solution and the reference solution, an HPLC-DAD fingerprint of the Chinese medicine compound is obtained; The chromatographic conditions for high performance liquid chromatography detection are as follows: a chromatographic column with octadecyl bonded silica as filler, mobile phase A is methanol:acetonitrile = 1:1, mobile phase B is 0.095% to 0.105% acetic acid aqueous solution, gradient elution program is: 0-15min, 15%→25%A; 15-60min, 25%→60%A; flow rate is 0.5-1.5mL / min, column temperature is 15-40℃, detection wavelength is 200-260nm, injection volume is 5-15μl; The specifications of the chromatographic column are as follows: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.

2. The construction method according to claim 1, characterized in that: In the preparation of the test solution, the water is purified water or distilled water.

3. The construction method according to claim 1, characterized in that: The container is a conical flask.

4. The construction method according to claim 1, characterized in that: In the preparation of the test solution, the mass / volume ratio between the Chinese medicine compound preparation and the water is 0.01-0.5, in units of g / ml.

5. The construction method according to claim 4, characterized in that: In the preparation of the test solution, the mass / volume ratio between the Chinese medicine compound preparation and the water is 0.076-0.084, in g / ml, or 0.019-0.021, in g / ml.

6. The construction method according to claim 1, characterized in that: The ultrasonic extraction time is 10 to 60 minutes.

7. The construction method according to claim 6, characterized in that: The ultrasonic extraction time is 28.5 to 31.5 minutes.

8. The construction method according to claim 1, characterized in that: The filtration is microporous membrane filtration.

9. The construction method according to claim 8, characterized in that: The pore size of the microporous filter membrane is 0.45 μm.

10. The construction method according to claim 1, characterized in that: The concentration of magnolidine in the reference solution is 450-550 μg / ml.

11. The construction method according to claim 1, characterized in that: The concentration of mangiferin in the reference solution is 450-550 μg / ml.

12. The construction method according to claim 1, characterized in that: The concentration of albiflorin in the reference solution is 450-550 μg / ml.

13. The construction method according to claim 1, characterized in that: The concentration of paeoniflorin in the reference solution is 450-550 μg / ml.

14. The construction method according to claim 1, characterized in that: The concentration of epimedin A in the reference solution is 450-550 μg / ml.

15. The construction method according to claim 1, characterized in that: The concentration of epimedin B in the reference solution is 450-550 μg / ml.

16. The construction method according to claim 1, characterized in that: The concentration of epimedin C in the reference solution is 450-550 μg / ml.

17. The construction method according to claim 1, characterized in that: The concentration of icariin in the reference solution is 450-550 μg / ml.

18. The construction method according to claim 1, characterized in that: The reference substance solution is a mixed solution of magnoliavine 475-525 μg / ml, mangiferin 475-525 μg / ml, paeoniflorin 475-525 μg / ml, paeoniflorin 475-525 μg / ml, epimedin A 475-525 μg / ml, epimedin B 475-525 μg / ml, epimedin C 475-525 μg / ml and icariin 475-525 μg / ml.

19. The construction method according to claim 1, characterized in that: The flow rate is 0.8-1.2 ml / min.

20. The construction method according to claim 19, characterized in that: The flow rate is 0.95-1.05 ml / min.

21. The construction method according to claim 1, characterized in that: The column temperature is 20-30°C.

22. The construction method according to claim 21, characterized in that: The column temperature is 23.75-26.25°C.

23. The construction method according to claim 1, characterized in that: The detection wavelength is 210-250 nm.

24. The construction method according to claim 23, characterized in that: The detection wavelength is 230 nm.

25. The construction method according to claim 1, characterized in that: The injection volume is 8 to 12 μl.

26. The construction method according to claim 25, characterized in that: The injection volume is 9.5-10.5 μl.

27. The construction method according to claim 1, characterized in that: The theoretical plate number of the chromatographic peak corresponding to the reference substance is 5000.

28. The construction method according to claim 1, characterized in that: The separation degree of the chromatographic peak corresponding to the reference substance is equal to 1.

5.

29. The construction method according to claim 1, characterized in that: The chromatographic column is a Kromasil 100-5-C18 chromatographic column, a Welch Ultimate XB-C18 chromatographic column or a Diamonsil C18 chromatographic column.

30. The construction method according to claim 29, characterized in that: The chromatographic column is a Kromasil 100-5-C18 chromatographic column.

31. The construction method according to claim 1, characterized in that: The preparation method of the traditional Chinese medicine compound preparation comprises: (1) weighing an appropriate amount of oysters and crushing them into oyster fine powder; and (2) weighing an appropriate amount of epimedium, radix scutellariae, rhizoma anemarrhenae, rhizoma rehmanniae, rhizoma sparganii, rhizoma curcumae, rhizoma ligustici and rhizoma peonyii, decocting them with water, filtering, concentrating the filtrate into a clear paste, adding the oyster fine powder, mixing, drying, crushing into fine powder, preparing the preparation, and drying.

32. The construction method according to claim 31, characterized in that: In step (2), appropriate amounts of starch and sucrose are added together with the oyster powder.

33. The construction method according to claim 31, characterized in that: The mass ratio of the epimedium, the Dipsacus asper, the Anemarrhena asphodeloides, the Rehmannia root, the Trillium, the Curcuma zedoaria, the Ligusticum chuanxiong, the Paeonia lactiflora and the oyster is (500-1000):(20-100):(20-100):(20-100):(20-100):(20-100):(20-100):(20-100):(5-20.

34. The construction method according to claim 33, characterized in that: The mass ratios of the epimedium, the Dipsacus asper, the Anemarrhena asphodeloides, the Rehmannia root, the Trillium, the Curcuma zedoaria, the Ligusticum chuanxiong, the Paeonia lactiflora and the Concha Ostreae are (617.5-682.5):(47.5-52.5):(47.5-52.5):(38-42):(47.5-52.5):(47.5-52.5):(47.5-52.5):(47.5-52.5):(9.5-10.5).

35. The construction method according to claim 31, characterized in that: The oyster is calcined oyster.

36. The construction method according to claim 31, characterized in that: The decoction is performed 1 to 5 times.

37. The construction method according to claim 36, characterized in that: The decoction was performed 3 times.

38. The construction method according to claim 31, characterized in that: The decoction time is 0.5 to 3 hours.

39. The construction method according to claim 38, characterized in that: The decocting time is 1 to 2 hours.

40. The construction method according to claim 31, characterized in that: The relative density of the clear paste at 50° C. is 1.2 to 1.

40.

41. The construction method according to claim 31, characterized in that: The relative density of the clear paste at 50° C. is 1.2825 to 1.4175.

42. The construction method according to claim 31, characterized in that: The dosage form of the Chinese medicine compound preparation is granules or capsules.

43. The construction method according to claim 42, characterized in that: The particles are sugar-containing particles or sugar-free particles.

44. The construction method according to claim 1, characterized in that: When the detection wavelength is 230 nm, the fingerprint spectrum includes peaks 1-13, among which peak 2 is magnolamine, peak 3 is mangiferin, peak 4 is paeoniflorin, peak 5 is paeoniflorin, peak 8 is epimedin A, peak 9 is epimedin B, peak 10 is epimedin C, and peak 11 is icariin.

45. The construction method according to claim 1, characterized in that: When the detection wavelength is 230nm, the fingerprint spectrum includes peaks 1-13, among which peak 1 belongs to the medicinal flavor of Dipsacus asper; peaks 3 and 7 belong to the medicinal flavor of Anemarrhena asphodeloides; peaks 2, 8, 9, 10, 11, 12 and 13 belong to the medicinal flavor of Epimedium; peaks 4 and 5 belong to the medicinal flavor of Paeonia lactiflora.

46. ​​The construction method according to claim 1, characterized in that When the detection wavelength is 230nm, the retention times of peaks 1-13 are 7.906±10%, 10.154±10%, 14.359±10%, 15.240±10%, 18.112±10%, 28.712±10%, 33.823±10%, 44.317±10%, 45.017±10%, 46.294±10%, 46.921±10%, 56.007±10% and 66.515±10%, respectively.

47. The construction method according to claim 1, characterized in that When the detection wavelength is 230nm, the peak areas of peaks 1-13 are 326893±10%, 3847512±10%, 297337±10%, 1334176±10%, 1598972±10%, 1226905±10%, 1099858±10%, 300925±10%, 366698±10%, 3332369±10%, 1954843±10%, 471566±10% and 600721±10%, respectively.

48. The construction method according to claim 1, characterized in that: When the detection wavelength is 230nm, the fingerprint spectrum includes 13 characteristic peaks, with the chromatographic peak of paeoniflorin No. 5 as the reference peak, and the relative retention times of the other 12 characteristic peaks are 0.433±10% for chromatographic peak No. 1, 0.568±10% for chromatographic peak No. 2, 0.792±10% for chromatographic peak No. 3, 0.840±10% for chromatographic peak No. 4, 1.548±10% for chromatographic peak No. 6, 1.877±10% for chromatographic peak No. 7, 2.453±10% for chromatographic peak No. 8, 2.498±10% for chromatographic peak No. 9, 2.561±10% for chromatographic peak No. 10, 2.598±10% for chromatographic peak No. 11, 3.110±10% for chromatographic peak No. 12 and 3.699±10% for chromatographic peak No.

13.

49. A quality control method for a Chinese medicinal compound containing Epimedium, characterized in that: The quality control method comprises the following steps: (1) Establishing a standard HPLC-DAD fingerprint of a Chinese medicine compound reference sample according to the HPLC-DAD fingerprint construction method described in any one of claims 1 to 48; (2) taking a solution of a Chinese medicine compound sample, and testing it according to the chromatographic conditions in the HPLC-DAD fingerprint construction method according to any one of claims 1 to 48 to obtain an HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested; as well as (3) Compare the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested obtained in step (2) with the HPLC-DAD fingerprint of the Chinese medicine compound reference sample standard obtained in step (1). The product that meets the requirements is qualified, and the product that does not meet the requirements is unqualified.

50. The quality control method according to claim 49, characterized in that: The compliance requirements include one or more of the following: (1) When the detection wavelength is 230 nm, the HPLC-DAD fingerprint spectrum of the Chinese medicine compound sample to be tested exhibits 13 characteristic chromatographic peaks, and the retention time of each characteristic chromatographic peak is within ±10% of the retention time value of the corresponding reference chromatographic peak in the standard HPLC-DAD fingerprint spectrum of the Chinese medicine compound reference sample; (2) When the detection wavelength is 230 nm, with the paeoniflorin peak as the S peak, the relative retention time of each characteristic chromatographic peak in the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested and the S peak is within ±10% of the relative retention time value of each characteristic chromatographic peak in the standard HPLC-DAD fingerprint of the Chinese medicine compound reference sample; and (3) According to the Chinese medicine chromatographic HPLC-DAD fingerprint similarity evaluation system, the similarity between the HPLC-DAD fingerprint of the Chinese medicine compound sample to be tested and the HPLC-DAD fingerprint of the Chinese medicine compound reference sample is calculated, and the similarity shall not be less than 0.

90.

51. Use of the construction method according to any one of claims 1 to 48 or the quality control method according to claim 49 or 50 in quality detection, quality evaluation or quality control of a traditional Chinese medicine compound containing Epimedium.